Cordis Corporation, a developer and manufacturer of interventional vascular technology, has launched ExoSeal Vascular Closure Device to provide secure extravascular arterial closure.
Cordis has received CE-marking approval for ExoSeal Vascular Closure Device in May 2010. The new product was launched during EuroPCR, the medical conference in Europe for physicians specialising in interventional cardiovascular medicine.
ExoSeal was shown in a recent clinical trial to have a positive clinical safety profile during vascular procedures. The ‘Eclipse Trial’ recorded no adverse clinical events and achieved a level of safety comparable to manual compression while reducing time to ambulation.
Campbell Rogers, chief scientific officer and global head of R&D at Cordis, said: “The ExoSeal Vascular Closure Device incorporates key advancements including the use of the Polyglycolic Acid Plug, two visual indicators to moderate control of the device and lockout features to reduce the risk of complications. The device is designed for ease of use, reducing the number of components and deployment steps.”